natgillin/translations-raw huggingface dataset:
In the trial for the prevention of clinical fractures following a recent hip fracture, vitamin D levels were not routinely measured but the majority of patients received a loading dose of vitamin D prior to Aclasta administration (see section 4.2).
U ispitivanju prevencije kliničkih prijeloma nakon nedavnog prijeloma kuka, razine vitamina D nisu se rutinski mjerile, ali je većina bolesnika primila dodatnu dozu vitamina D prije primjene Aclaste (vidjeti dio 4.2).
In the trial for the prevention of clinical fractures following a recent hip fracture, vitamin D levels were not routinely measured but the majority of patients received a loading dose of vitamin D prior to zoledronic acid administration (see section 4.2).
U ispitivanju prevencije kliničkih prijeloma nakon nedavnog prijeloma kuka, razine vitamina D nisu se rutinski mjerile, ali je većina bolesnika primila dodatnu dozu vitamina D prije primjene zoledronatne kiseline (vidjeti dio 4.2).
In the TRYPHAENA trial, the incidence of NCI-CTCAE v.3 Grade 3-4 neutropenia was 85.3% in patients treated with neoadjuvantPerjeta + TCH and 77.0% in patients treated with neoadjuvant Perjeta, trastuzumab and docetaxel following FEC, including 66.7% and 59.5% Grade 4 neutropenia, respectively.
U ispitivanju TRYPHAENA, incidencija neutropenije stupnja 3-4 prema verziji 3 NCI-CTCAE kriterija iznosila je 85,3% u bolesnika neoadjuvantno liječenih lijekom Perjeta + TCH-om te 77,0% u onih koji su neoadjuvantno primali lijek Perjeta, trastuzumab i docetaksel nakon FEC-a, uključujući neutropeniju stupnja 4 u 66,7% odnosno 59,5% slučajeva.
In the TVC and TVC-naïve cohorts, the vaccine’s efficacy was demonstrated against high-grade cervical lesions at end of study (Table 5).
U TVC i TVC-neizloženim kohortama, djelotvornost cjepiva je pokazana na cervikalnim lezijama visokog stupnja na kraju ispitivanja (Tablica 5).
In the two 12 weeks studies (Trials 1 and 2), 739 patients received ospemifene and 724 patients received placebo.
U dva ispitivanja u trajanju od 12 tjedana (ispitivanje 1 i 2), 739 bolesnica primalo je ospemifen a 724 je primalo placebo.
In the two double-blind, placebo–controlled phase 3 studies in Peyronie’s disease, 65.5% of Xiapex-treated patients developed penile haematoma and 14.5% developed penile ecchymosis.
U dva dvostruko slijepa, placebom kontrolirana ispitivanja faze III u Peyronijevoj bolesti 65,5% bolesnika liječenih Xiapexom razvilo je hematom penisa i 14,5% ekhimozu penisa.
In the two observational studies, 12.1% and 33.1% of the patients had brain metastases at the time of advanced melanoma diagnosis.
U dva opservacijska ispitivanja sudjelovalo je 12.1% i 33.1% bolesnika koji su imali metastaze na mozgu kada im je dijagnosticiran uznapredovali melanom.
In the two ongoing studies (ELT116826 and ELT116643), cytogenetic abnormalities have been detected in 4/28 (14%) and 4/62 (6%) subjects in each study.
U dva ispitivanja koja su u tijeku (ELT116826 i ELT116643), citogenetske abnormalnosti uočene su u 4/28 (14%) i 4/62 (6%) ispitanika u svakom od ispitivanja.
In the two other studies, Rasagiline ratiopharm was given as ‘add-on’ to patients with later stage disease who were already being treated with levodopa, and compared with placebo and another medicine entacapone (also used as add-ons).
U druga dva ispitivanja, Razagilin ratiopharm primijenjen je kao dodatna terapija u bolesnika s kasnijim stadijem bolesti koji su već liječeni levodopom, i uspoređen je s placebom i drugim lijekom entakaponom (koji se također koristi u dodatnim terapijama).
In the two Phase 3 double-blind placebo controlled studies, most adverse reactions were local events of the penis and groin and the majority of these events were of mild or moderate severity, and most (79%) resolved within 14 days of the injection.
U ta dva dvostruko slijepa, placebom kontrolirana ispitivanja faze 3, većina nuspojava bile su lokalne pojave u području penisa i prepona, većinom su bile blage ili umjerene težine i većina (79%) ih se povukla unutar 14 dana od injekcije.
In the two Phase III studies in non-Hodgkin’s lymphoma and multiple myeloma patients (AMD3100-3101 and AMD3100-3102, respectively), a total of 301 patients were treated in the Mozobil and G-CSF group and 292 patients were treated in the placebo and G-CSF group.
U dvama ispitivanjima faze III u bolesnika s ne-Hodgkinovim limfomom (AMD3100-3101) i multiplim mijelomom (AMD3100-3102) ukupno je 301 bolesnik primao Mozobil i G-CSF, a 292 bolesnika placebo i G-CSF.
In the two Phase III studies, 4 out of 563 (0.7%) patients in the 10 mg/kg group and 27 out of 559 (4.8%) patients in the 1 mg/kg group tested positive for persistent presence of anti-belimumab antibodies.
U dvije studije Faze III, 4 od 563 (0,7%) bolesnika u skupini koja je primala lijek Benlysta 10 mg/kg, te 27 od 559 (4,8%) bolesnika u skupini koja je primala lijek Benlysta u dozi od 1 mg/kg, bilo je pozitivno na stalnu prisutnost anti-belimumab protutijela.
In the two placebo-controlled phase III trials, tests on thyroid stimulating hormone (TSH) showed post baseline >ULN in 26.1% of patients treated with Stivarga and in 15.1% of patients receiving placebo.
U dva placebom kontrolirana ispitivanja faze III, testovi hormona koji stimulira štitnjaču (TSH) pokazali su naknadnu početnu vrijednost > GGN u 26,1% bolesnika liječenih lijekom Stivarga i u 15,1% bolesnika koji su primali placebo.
In the two placebo-controlled phase III trials, the overall incidence of hemorrhage was 19.3% in patients treated with Stivarga.
U dva placebom kontrolirana ispitivanja faze III, ukupna incidencija krvarenja bila je 19,3% u bolesnika liječenih lijekom Stivarga.
In the two studies of brain and spine abnormalities taken together, scans taken with Optimark had a score increase of 0.63 points on average from a ‘baseline’ of 1.58 points without Optimark.
U okviru dvaju ispitivanja abnormalnosti mozga i kralježnice koja su provedena zajedno, prikazi snimljeni uz primjenu lijeka Optimark pokazali su prosječno povećanje rezultata od 0,63 boda u odnosu na osnovnu vrijednost od 1,58 bodova bez primjene lijeka Optimark.
In the two studies, NEVANAC cleared inflammation at day 14 post operation in 65% and 68% of patients compared to 25% and 35% of patients on vehicle.
U dva ispitivanja, NEVANAC je uklonio upalu na dan 14 nakon operacije kod 65 % i 68% bolesnika u usporedbi sa 25% i 35% bolesnika na podlozi lijeka.
In the two studies, the average amount of phosphate in the blood during treatments with Sevelamer carbonate Zentiva or Renagel was similar.
U oba ispitivanja prosječna količina fosfata u krvi tijekom terapija s lijekovima Sevelamer carbonate Zentiva ili Renagel bila je podjednaka.
In the two surgeries that occurred during the study, Nuwiq was rated as excellent in preventing bleeding episodes.
U dva kirurška zahvata koja su se dogodila tijekom ispitivanja Nuwiq je ocijenjen kao izvrstan u sprječavanju epizoda krvarenja.
In the two-year placebo-controlled study, hypertension was reported as an adverse event in 6.5% of patients on fingolimod 0.5 mg and in 3.3% of patients on placebo.
U dvogodišnjem placebom kontroliranom ispitivanju, hipertenzija je bila prijavljena kao štetan događaj u 6,5% bolesnika liječenih s 0,5 mg fingolimoda te u 3,3% bolesnika liječenih placebom.
In the twoplacebo-controlled studies adverse events were generally mild to moderate in severity.
U ta dva placebom kontrolirana ispitivanja nuspojave su općenito bile blage do umjerene u težini.
In the unadjuvanted control group, as well as in the adjuvant control group, all animals died or had to be euthanized as they were moribund, three to four days after the start of challenge.
U kontrolnoj skupini bez adjuvansa, kao i u kontrolnoj skupini s adjuvansom, tri do četiri dana nakon opterećenja sve su životinje umrle ili morale biti eutanazirane jer su bile na umoru.
In the urine, unchanged ataluren and the acyl glucuronide metabolite account for <1% and 49%, respectively, of the administered dose.
U urinu, neizmijenjeni ataluren čini <1%, a metabolit acil glukuronida 49% primijenjene doze.
In the US study, a total of 49 subjects with primary immunodeficiency syndromes aged between 5 and 72 years old were treated with Hizentra for up to 15 months.
U američkoj studiji, ukupno 49 ispitanika sa sindromom primarne imunodeficijencije u dobi između 5 i 72 godina bilo je liječeno Hizentrom do 15 mjeseci.
In the USA, generalised vaccination with Prevenar using a four-dose series in infants and a catch-up programme for children up to 5 years of age was introduced in 2000.
U Sjedinjenim Američkim Državama je 2000. godine uvedeno generalizirano cijepljenje Prevenarom u seriji od četiri doze u dojenčadi i program nadoknade cijepljenja u djece u dobi do 5 godina.
In the vandetanib arm, a total of 73 (32%) patients progressed: 64 (28%) by response evaluation criteria in solid tumours (RECIST) progression and 9 (4%) by death in the absence of progression.
U skupini koja je primala vandetanib, ukupno je u 73 bolesnika (32%) došlo do progresije: U 64 bolesnika (28%) progresija je utvrđena prema mjerilima za ocjenu odgovora u solidnim tumorima (engl. response evaluation criteria in solid tumours, RECIST), a 9 bolesnika (4%) je umrlo, a da nije došlo do progresije.
In the varenicline group compared to placebo, a higher proportion of subjects reported suicidal ideation or behaviour prior to enrolment (lifetime history) and after the end of active treatment period (on Days 33 to 85 after the last dose of treatment).
U skupini koja je primala vareniklin je u odnosu na skupinu koja je primala placebo veći broj ispitanika prijavio suicidalne ideje ili ponašanje prije uključivanja u ispitivanje (cjeloživotna anamneza) i nakon završetka razdoblja aktivnog liječenja (od 33. do 85. dana nakon posljednje doze liječenja).
In the varenicline group compared to placebo, a higher proportion of subjects reported suicidal ideation or behaviour prior to enrolment (lifetime history) and after the end of active treatment period (on Days 33 to 85 after the last dose of treatments ).
U skupini koja je primala vareniklin je u odnosu na skupinu koja je primala placebo veći broj ispitanika prijavio suicidalne ideje ili ponašanje prije uključivanja u ispitivanje (cjeloživotna anamneza) i nakon završetka razdoblja aktivnog liječenja (od 33. do 85. dana nakon posljednje doze liječenja).
In the VcR-CAP group, 22.5% of patients received platelet transfusions compared to 2.9% of patients in the R-CHOP group.
U VcR-CAP skupini, 22,5% bolesnika primilo je transfuzije trombocita u usporedbi s 2,9% bolesnika u R-CHOP skupini.
in the veins (thrombosis)
u venama (tromboza)
In the veins, particularly of the legs (deep vein thrombosis)
U venama, posebice u venama nogu (duboka venska tromboza)
In the VIBRANT study, the primary efficacy endpoint was the proportion of patients who gained at least 15 letters in BCVA at week 24 compared to baseline and the Eylea group was superior to laser control.
U ispitivanju VIBRANT primarni je ishod djelotvornosti bio udio bolesnika koji su dobili najmanje 15 slova prema BCVA mjereno u 24. tjednu u odnosu na početnu vrijednost, a skupina koja je primala lijek Eylea bila superiornija prema kontrolnoj skupini.
In the VIBRANT study, the primary efficacy endpoint was the proportion of patients who gained at least 15 letters in BCVA at week 24 compared to baseline and the Eylea group wassuperior to laser control.
U ispitivanju VIBRANT primarni je ishod djelotvornosti bio udio bolesnika koji su dobili najmanje 15 slova prema BCVA mjereno u 24. tjednu u odnosu na početnu vrijednost, a skupina koja je primala lijek Eylea bila superiornija prema kontrolnoj skupini.
In the ViraferonPeg combination trial, 1,530 naïve patients were treated for one year with one of the following combination regimens:
U ispitivanju lijeka ViraferonPeg u kombinaciji s ribavirinom, 1530 bolesnika koji prethodno nisu bili liječeni primalo je tijekom godine dana jedan od sljedeća tri režima kombinirane terapije:
In the VTEp studies, in total, 11% of the patients treated with apixaban 2.5 mg twice daily experienced adverse reactions.
U ispitivanjima prevencije venskih tromboembolijskih događaja nuspojave su se pojavile u ukupno 11% bolesnika liječenih apiksabanom u dozi od 2,5 mg dvaput na dan.
In the Week 96 pooled analysis for patients receiving emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) + rilpivirine hydrochloride in the Phase 3 clinical studies TMC278-C209 and TMC278-C215, HIV-1 isolates from 43 patients had an amino acid substitution associated with NNRTI (n = 39) or NRTI (n = 41) resistance.
U objedinjenoj analizi u 96. tjednu za bolesnike koji su primali emtricitabin/tenofovirdizoproksilfumarat (FTC/TDF)+rilpivirinklorid u kliničkim ispitivanjima TMC278-C209 i TMC278-C215 faze 3, HIV-1 izolati 43 bolesnika imali su supstituciju aminokiselina povezanu s NNRTI (n = 39) ili NRTI (n = 41) rezistencijom.
In the week 96 pooled resistance analysis for patients receiving emtricitabine/tenofovir disoproxil fumarate + rilpivirine hydrochloride in the Phase III clinical studies C209 and C215, there were 78 virologic failure patients with genotypic resistance information available for 71 of those patients.
U analizi objedinjenih podataka o rezistenciji iz 96. tjedna za pacijente koji su primali emtricitabin/tenofovirdizoproksilfumarat + rilpivirinklorid u III. fazi kliničkih ispitivanja C209 i C215, u 78 pacijenata postojao je virološki neuspjeh, a genotipski podaci o rezistenciji bili su dostupni za 71 od tih pacijenata.
In the younger age groups (2-6 years and 7-11 years), total clearance was higher compared with that in adolescents, resulting in a lower level of exposure (AUC and Cmax) and elimination half-life.
U mlađim dobnim skupinama (2-6 godina i 7-11 godina), ukupni je klirens bio veći u odnosu na skupinu adolescenata, što je dovelo do niže razine izloženosti (AUC i Cmax) i kraćeg poluvremena eliminacije.
In the “crimped area” on either side of the ampoule tail
Na "naboranom dijelu" svake strane repa ampule
In the “Prevention Regimen For Effectively avoiding Second Strokes” (PRoFESS) trial in patients 50 years and older, who recently experienced stroke, an increased incidence of sepsis was noted for telmisartan compared with placebo, 0.70 % vs.
U ispitivanju „Preventivni režim za učinkovito izbjegavanje drugog moždanog udara“ (PRoFESS, od engl.“Prevention Regimen For Effectively avoiding Second Strokes”) u bolesnika u dobi od 50 godina i starijih, koji su nedavno imali moždani udar, zabilježena je povećana incidencija sepse za telmisartan u usporedbi s placebom, 0,70 % u odnosu na 0,49 % RR 1,43 (95 % interval pouzdanosti 1,00 – 2,06).
In these 52-week duration studies, patients received treatment for 12 weeks, followed by a 40-week non-treatment phase.
U tim ispitivanjima u trajanju od 52 tjedna bolesnici su liječeni 12 tjedana, nakon čega je uslijedila faza od 40 tjedana bez terapije.
In these cases it is therefore recommended that the Zonegran total dose should be rounded up or down to the nearest available dose that can be achieved with commercially available tablet strengths of Zonegran (25 mg, 50 mg, 100 mg and 300 mg).
Stoga se u tim slučajevima preporučuje zaokružiti ukupnu dozu Zonegrana na najbližu višu ili nižu moguću dozu koja se može postići jačinama tableta Zonegrana dostupnim na tržištu (25 mg, 50 mg, 100 mg i 300 mg).
In these cases Pramipexole Teva may affect your ability to drive and operate machinery.
U tim slučajevima Pramipeksol Teva može utjecati na Vašu sposobnost upravljanja vozililima i strojevima.
In these cases, epoetin alfa is used to replace the missing hormone or to increase red blood cell counts.
U tim slučajevima se epoetin alfa koristi kao zamjena za hormon koji nedostaje ili za povećanje broja crvenih krvnih stanica.
In these cases, epoetin alfa is used to replace the missing hormone or to increase red blood cell counts.
U tim slučajevima, epoetin alfa koristi se kao zamjena za hormon koji nedostaje ili za povećanje broja crvenih krvnih stanica.
In these cases, if clinically appropriate, higher cut-off levels of platelet count for dose reduction (200 x 109/l) and treatment interruption (400 x 109/l) may be considered according to medical judgement.
U tim slučajevima, ako je klinički opravdano, povišena gornja vrijednost trombocita može biti prihvatljiva ovisno o medicinskoj procjeni i to kod sniženja doze (200 x 109/l) i kod prekida liječenja (400 x 109/l).
In these cases, it is also recommended to check renal function before initiating treatment with metformin.
U tim se slučajevima također preporučuje provjera funkcije bubrega prije započinjanja liječenja metforminom.
In these cases, it is also recommended to check renal function before initiating treatment with Synjardy.
U tim se slučajevima također preporučuje provjera funkcije bubrega prije započinjanja liječenja Synjardyem.
In these cases, it is recommended that you are monitored during the first infusion and for an hour afterwards.
U tim slučajevima, bit ćete pomno nadzirani tijekom cijele infuzije i najmanje 1 sat nakon nje.
In these cases, PAH was reported after initiation of dasatinib therapy, including after more than one year of treatment.
U tim je slučajevima PAH bio zabilježen nakon početka terapije dasatinibom, pa čak i nakon više od godine dana liječenja.
In these cases, Perjeta is used together with trastuzumab and docetaxel (other cancer medicines).
U ovim slučajevima, Perjeta se koristi zajedno s trastuzumabom i doketakselom (drugim lijekovima protiv raka).
In these cases, Perjeta is used with trastuzumab and chemotherapy.
U ovim slučajevima, Perjeta se koristi zajedno s trastuzumabom i kemoterapijom.
In these cases, the dose of ciclosporin should be gradually reduced to zero over four to eight weeks, and the dose of Rapamune increased to obtain blood levels of sirolimus of about 12 to 20 ng/ml.
U tim slučajevima, dozu ciklosporina treba postupno smanjivati do nule tijekom četiri do osam tjedana, a dozu lijeka Rapamune treba povećati kako bi se dobile koncentracije sirolimusa u krvi koje iznose otprilike 12 do 20 ng/ml.
In these cases, treatment should be discontinued (see section 4.3).
U takvim slučajevima liječenje treba prekinuti (vidjeti dio 4.3).
In these categories of animals the vaccine should be used only according to the benefit-risk assessment by the responsible veterinarian and/or the national Competent Authorities, depending on the current vaccination policies against bluetongue virus.
U ovih kategorija životinja cjepivo treba koristiti samo prema procjeni odnosa koristi i rizika, od strane odgovornog veterinara i/ili nacionalnih nadležnih tijela, ovisno o važećim odredbama cijepljenja protiv bolesti plavog jezika.
In these children, the use of Diacomit will be done under the close supervision of the doctor.
U ove će se djece stiripentol primjenjivati uz strogi nadzor liječnika.
In these circumstances pertussis vaccination should be discontinued and the vaccination course should be continued with diphtheria-tetanus, hepatitis B, polio and Hib vaccines.
U tom slučaju treba prekinuti cijepljenje protiv pertusisa i nastaviti program imunizacije cjepivima protiv difterije- tetanusa, hepatitisa B, poliomijelitisa i Hib-a.
In these clinical studies, discontinuation due to adverse events, regardless of causality, was observed in 11.3% of patients.
U tim kliničkim ispitivanjima prekidi terapije uzrokovani štetnim događajima, bez obzira na uzročno- posljedičnu vezu, uočeni su u 11,3% bolesnika.
In these clinical studies, the median time to onset of the first occurrence of haemorrhagic events was 94 days in both studies for the combination of trametinib and dabrafenib.
U tim kliničkim ispitivanjima medijan vremena do prve pojave krvarenja bio je 94 dana u oba ispitivanja za kombinaciju trametiniba i dabrafeniba.
In these clinical trials, approximately 43% of patients experienced at least one adverse reaction during Velphoro treatment, which were reported as serious adverse reactions in 0.36%.
U kliničkim ispitivanjima, za vrijeme liječenja lijekom Vephoro u približno 43% bolesnika pojavila se najmanje jedna nuspojava, koja je u 0,36% slučajeva prijavljena kao ozbiljna nuspojava.
In these clinical trials, clinically significant increases (greater than 3 x Upper Limit of Normal) in serum alanine aminotransferase (ALT), along with clinically significant increases (greater than 2 x Upper Limit of Normal) in serum total bilirubin were observed in 3 patients treated with tolvaptan.
U tim kliničkim ispitivanjima, u 3 bolesnika liječenih tolvaptanom, zabilježena su klinički značajna (više od 3 x od gornje granice normalnih vrijednosti (GGN)) povišenja vrijednosti alanin aminotransferaze (ALT) u serumu, kao i klinički značajan porast (veći od 2 x od gornje granice normalnih vrijednosti ) serumskog bilirubina.
In these clinical trials, clinically significant increases (greater than 3 x Upper Limit of Normal) in serum alanine aminotransferase (ALT), along with clinically significant increases (greater than 2 x Upper Limit of Normal) in serum total bilirubin were observed in 3 patients treated with tolvaptan.
U tim kliničkim ispitivanjima, u 3 bolesnika liječenih tolvaptanom, zabilježena su klinički značajna (više od 3 x od gornje granice normalnih vrijednosti (GGN)) povišenja vrijednosti alanin aminotransferaze (ALT) u serumu, kao i klinički značajan porast (veći od 2 x od gornje granice normalnih vrijednosti) serumskog bilirubina.
In these diseases, Lucentis can help to stabilise and in many cases improve your vision.
U ovim bolestima Lucentis može pomoći stabilizirati, a u mnogim slučajevima i poboljšati Vaš vid.
In these extensions clinical studies, no cases of high-grade intraepithelial neoplasia and no cases of genital warts were observed in subjects who received qHPV vaccine in the base study:
U gore navedenim produžecima kliničkih ispitivanja, u ispitanika koji su primili qHPV cjepivo u temeljnom ispitivanju nije bilo opaženih slučajeva intraepitelnih neoplazija visokog stupnja niti slučajeva genitalnih bradavica:
In these individuals, an adequate immune response may not be elicited.
U tih pojedinaca, možda se neće postići odgovarajući imunološki odgovor.
In these induction studies, efficacy was higher and better sustained in the tiered dose group compared to the 130 mg dose group, and tiered dosing is therefore the recommended intravenous induction dose.
U ovim ispitivanjima uvodnog liječenja, djelotvornost je bila viša i bolje se održala u skupini s dozama određinima prema tjelesnoj težini u usporedbi sa skupinom s dozom od 130 mg, te se stoga doziranje određeno prema tjelesnoj težini preporučuje za intravensku uvodnu dozu.
In these patient groups, urinary copper levels should be kept a little above the upper limit of normal or in the high normal range (i.e.
Kod ovih skupina bolesnika, razinu bakra u mokraći treba održavati malo iznad gornje granice normalne vrijednosti ili u rasponu visokih normalnih vrijednosti (tj.
In these patients hypoglycaemia may occur under telmisartan treatment.
U ovoj skupini bolesnika može doći do pojave hipoglikemije tijekom liječenja telmisartanom.
In these patients it is recommended that an electrocardiogram (ECG) is recorded before initiation of treatment with Trobalt and in those with a corrected QT interval >440ms at baseline, an ECG should be recorded on reaching the maintenance dose.
Prije započinjanja terapije lijekom Trobalt, kod navedenih bolesnika preporučuje se snimiti elektrokardiogram (EKG), a u onih s početnim korigiranim QT intervalom >440 ms treba snimiti EKG i nakon postizanja doze održavanja.
In these patients one should consider doubling the timing of removal of a catheter, at least 24 hours for the lower prescribed dose of enoxaparin (30 mg once daily) and at least 48 hours for the higher dose (1 mg/kg bw/day).
U tih je bolesnika potrebno razmotriti dvostruko duže vrijeme za uklanjanje katetera, najmanje 24 sata za propisanu nižu dozu enoksaparina (30 mg jedanput na dan) i najmanje 48 sati za više doze (1 mg/kg/dan).